Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

• Status: Recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

1. Males and females between 18 and 80 years of age

2. HF, confirmed with the increased level of NT-proBNP>300 pg/mL or BNP>100 pg/mL

3. Transthyretin amyloid cardiomyopathy, confirmed with echocardiography and/or contrast-enhanced cardiac MRI

Exclusion Criteria:

1. The inability to continue all the activities planned in this study by the patient.

2. The onset of pregnancy.

3. Patient's voluntary withdrawal of consent to participate in a clinical trial at any point during the conduct of the study.

4. Development of intolerable side effects.

5. Administration of disease-modifying treatment of amyloidosis.